These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26259807)

  • 1. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
    Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
    Park H; Jeong Y; Hong S
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1027-30. PubMed ID: 22196123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors.
    Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
    Dorn A; Schattel V; Laufer S
    Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
    J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.
    Laufer SA; Ahrens GM; Karcher SC; Hering JS; Niess R
    J Med Chem; 2006 Dec; 49(26):7912-5. PubMed ID: 17181176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors.
    Vogt D; Weber J; Ihlefeld K; Brüggerhoff A; Proschak E; Stark H
    Bioorg Med Chem; 2014 Oct; 22(19):5354-67. PubMed ID: 25150091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies.
    Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT
    Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.
    Karcher SC; Laufer SA
    J Med Chem; 2009 Mar; 52(6):1778-82. PubMed ID: 19253982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept.
    Hasumi K; Sato S; Saito T; Kato JY; Shirota K; Sato J; Suzuki H; Ohta S
    Bioorg Med Chem; 2014 Aug; 22(15):4162-76. PubMed ID: 24938496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
    Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.